-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UuhlR2YVL4TuuEz3gWzGYUuYbo6iFBABJiNLxtFGeRcx6J+QdrkG0XmE9FGKn1lx D4frrzVla1z2rI/Cfe9XiQ== 0001209191-11-010621.txt : 20110217 0001209191-11-010621.hdr.sgml : 20110217 20110217165615 ACCESSION NUMBER: 0001209191-11-010621 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110215 FILED AS OF DATE: 20110217 DATE AS OF CHANGE: 20110217 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DERMA SCIENCES, INC. CENTRAL INDEX KEY: 0000892160 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 232328753 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 214 CARNEGIE CENTER, SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6095144744 MAIL ADDRESS: STREET 1: 214 CARNEGIE CENTER, SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DERMA SCIENCES INC DATE OF NAME CHANGE: 19940513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WESSON BRUCE F CENTRAL INDEX KEY: 0001058190 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-13070 FILM NUMBER: 11621499 MAIL ADDRESS: STREET 2: 1827 PACIFIC ST CITY: BROOKLYN STATE: NY ZIP: 11233 FORMER NAME: FORMER CONFORMED NAME: WESSON BRUCE T DATE OF NAME CHANGE: 19980319 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2011-02-15 0 0000892160 DERMA SCIENCES, INC. DSCI 0001058190 WESSON BRUCE F C/O GALEN MANAGEMENT, L.L.C. 680 WASHINGTON BLVD. STAMFORD CT 06901 1 0 0 0 Common Stock 2011-02-15 4 S 0 56751 10.1016 D 16801 I See FN Common Stock 2011-02-15 4 S 0 600 11.3583 D 16201 I See FN Common Stock 2011-02-16 4 S 0 16201 10.3092 D 0 I See FN Common Stock 3125 D The shares were sold as follows: 52,383 by Galen Partners III, L.P. ("Galen III"), 4,753 by Galen Partners International III, L.P. ("Galen International III") and 215 by Galen Employee Fund III, L.P. ("Employee Fund III"). The shares were sold at prices between $10.00 and $10.26. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Following the sales on 2/15/11, the shares were held as follows: 14,797 by Galen III, 1,342 by Galen International III and 62 by Employee Fund III. Claudius, L.L.C. ("Claudius") serves as the sole General Partner of Galen III and Galen International III and has sole voting and invetment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Wesson Enterprises, Inc. ("Wesson") serves as the sole General Partner of Employee Fund III and has sole voting and investment control over the shares held by such fund and may be deemed to beneficially own the shares held by such fund. The Reporting Person is a member of Claudius and the sole shareholder of Wesson. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his pecuniary interest therein. The shares were sold at prices between $11.25 and $11.48. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The shares were sold as follows: 14,797 by Galen III, 1,342 by Galen International III and 62 by Employee Fund III. The shares were sold at prices between $10.11 and $10.67. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Following the sales on 2/16/11, no shares of common stock were held by Galen III, Galen International III or Employee Fund III. /s/ Bruce Wesson 2011-02-17 -----END PRIVACY-ENHANCED MESSAGE-----